The value of oxybutynin in transdermal patches for treating overactive bladder

详细信息    查看全文

• 作者：J. Salinas-Casado^a ; ^{jsalinascasado@yahoo.es" class="auth_mail" title="E-mail the corresponding author} ; M. Esteban-Fuertes^b ; O. Serrano^c ; J. Galvá ; n^c
• 关键词：Overactive bladder ; Oxybutynin ; Urinary incontinence ; Transdermal administration ; Anticholinergic agents ; Transdermal oxybutynin
• 刊名：Actas Urológicas Espa?olas (English Edition)
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：39
• 期：10
• 页码：599-604
• 全文大小：623 K

文摘

There is currently a broad therapeutic arsenal of drugs for treating overactive bladder syndrome (OAB). However, there is still a need for new compounds and for improving known drugs in terms of efficacy, compliance and tolerability.

Objective

To report the scientific evidence on the safety and efficacy of transdermal oxybutynin (OXY-TDS) for treating OAB.

Material and methods

A systematic review without time restrictions was conducted until May 2015 in the MEDLINE/PubMed database. We also performed a manual review of abstracts published in international urogynaecology congresses.

Results

The evaluated studies show that patients treated with OXY-TDS experience a significant reduction in urinary incontinence episodes compared with placebo, which is comparable to that observed in patients treated with oral oxybutynin or with tolterodine. In all of the studies, we observed improvements in symptoms from the second or third week of treatment and in a sustained manner until the end of treatment (6, 12 or 24 weeks). The clinical practice study also showed improved quality of life, achieving benefits in numerous patient profiles, with an efficacy independent of previous treatments. The safety of the drug was demonstrated in the various patient profiles.

Conclusions

OXY-TDS represents an effective alternative for the symptomatic treatment of adult patients with OAB, which, thanks to its pharmacokinetic profile, better tolerability, different administration method and dosage, could represent an added value in treating special populations.